Castle Biosciences Inc. (CSTL) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
505 S FRIENDSWOOD DRIVE FRIENDSWOOD, TX 77546 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 8071 - Medical Laboratories (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 243,099 | 258,625 | 329,633 | 409,852 | 98,845 | |||
| Cash and cash equivalents | 98,841 | 122,948 | 329,633 | 409,852 | 98,845 | |||
| Short-term investments | 144,258 | 135,677 | ||||||
| Receivables | 38,302 | 23,476 | 17,282 | 12,759 | 14,648 | |||
| Inventory, net of allowances, customer advances and progress billings | 7,942 | 3,980 | 2,021 | 2,217 | 1,237 | |||
| Inventory | 7,942 | 3,980 | 2,021 | 2,217 | 1,237 | |||
| Other undisclosed current assets | 6,292 | 6,207 | 4,807 | 4,766 | 1,951 | |||
| Total current assets: | 295,635 | 292,288 | 353,743 | 429,594 | 116,681 | |||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 91 | 229 | ||||||
| Operating lease, right-of-use asset | 12,306 | 12,181 | 7,383 | |||||
| Property, plant and equipment | 14,315 | 7,102 | 2,060 | |||||
| Long-term investments and receivables | 1,191 | 1,087 | 1,308 | 1,096 | 870 | |||
| Accounts and financing receivable, after allowance for credit loss | 1,191 | 1,087 | 1,308 | 1,096 | 870 | |||
| Intangible assets, net (including goodwill), including: | 117,335 | 126,348 | 88,922 | (275) | ||||
| Goodwill | 10,700 | 10,692 | ||||||
| Intangible assets, net (excluding goodwill) | 106,643 | 115,656 | 88,922 | (275) | ||||
| Other undisclosed intangible assets, net (including goodwill) | (8) | |||||||
| Other noncurrent assets | 1,440 | 1,110 | 1,715 | 1,536 | 135 | |||
| Other undisclosed noncurrent assets | 25,342 | 9,272 | 275 | |||||
| Total noncurrent assets: | 157,705 | 155,041 | 108,829 | 9,734 | 3,065 | |||
| TOTAL ASSETS: | 453,340 | 447,329 | 462,572 | 439,328 | 119,746 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 46,530 | 34,351 | 23,707 | 14,261 | 9,456 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 15,483 | 9,108 | 5,779 | ||
| Accounts payable | 10,268 | 4,731 | 2,546 | 2,098 | 1,865 | |||
| Accrued liabilities | 36,262 | 29,620 | 5,678 | 3,055 | 1,812 | |||
| Deferred revenue | 6,615 | |||||||
| Debt | 71 | 148 | 105 | 5,833 | ||||
| Other undisclosed current liabilities | 1,066 | 1,629 | 1,074 | |||||
| Total current liabilities: | 47,667 | 36,128 | 24,886 | 20,876 | 15,289 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 7,024 | 19,289 | ||||||
| Long-term debt, excluding current maturities | 19,289 | |||||||
| Finance lease, liability | 124 | |||||||
| Liabilities, other than long-term debt | 14,404 | 12,051 | 759 | 2,761 | 55 | |||
| Deferred revenue | 1,735 | |||||||
| Deferred rent credit | 1,026 | 55 | ||||||
| Deferred income tax liabilities | 206 | 428 | 635 | |||||
| Other liabilities | 25 | 90 | 124 | |||||
| Operating lease, liability | 14,173 | 11,533 | 6,900 | |||||
| Other undisclosed noncurrent liabilities | 18,163 | |||||||
| Total noncurrent liabilities: | 14,404 | 12,051 | 25,946 | 2,761 | 19,344 | |||
| Total liabilities: | 62,071 | 48,179 | 50,832 | 23,637 | 34,633 | |||
| Equity | ||||||||
| Equity, attributable to parent, including: | 391,269 | 399,150 | 411,740 | 415,691 | 85,113 | |||
| Additional paid in capital | 609,477 | 560,409 | 505,482 | 478,162 | 137,308 | |||
| Accumulated other comprehensive income (loss) | 136 | (381) | ||||||
| Accumulated deficit | (218,371) | (160,905) | (93,767) | (62,496) | (52,212) | |||
| Other undisclosed equity, attributable to parent | 27 | 27 | 25 | 25 | 17 | |||
| Total equity: | 391,269 | 399,150 | 411,740 | 415,691 | 85,113 | |||
| TOTAL LIABILITIES AND EQUITY: | 453,340 | 447,329 | 462,572 | 439,328 | 119,746 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 219,788 | 137,039 | 94,085 | 62,649 | 51,865 | ||
| Cost of revenue | (44,982) | (32,009) | (15,822) | (9,685) | (7,310) | ||
| Cost of goods and services sold | (15,822) | (9,685) | (7,310) | ||||
| Gross profit: | 174,806 | 105,030 | 78,263 | 52,964 | 44,555 | ||
| Operating expenses | (242,783) | (196,172) | (118,342) | (61,388) | (37,227) | ||
| Other operating income, net | 1,882 | ||||||
| Other undisclosed operating income | 18,287 | ||||||
| Operating income (loss): | (67,977) | (72,855) | (40,079) | (6,542) | 7,328 | ||
| Nonoperating income (expense) | 3,968 | 68 | 373 | (2,621) | |||
| Investment income, nonoperating | 3,968 | 68 | 373 | 312 | |||
| Other nonoperating expense | (2,933) | ||||||
| Interest and debt expense | (11) | (17) | (1) | (4,031) | 642 | ||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||||
| Income (loss) from continuing operations before income taxes: | (67,988) | (68,904) | (40,012) | (10,200) | 5,349 | ||
| Income tax expense (benefit) | (101) | 1,766 | 8,720 | (84) | (72) | ||
| Income (loss) from continuing operations: | (68,089) | (67,138) | (31,292) | (10,284) | 5,277 | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (31,292) | (10,284) | 5,277 | |
| Net income (loss): | (68,089) | (67,138) | (31,292) | (10,284) | 5,277 | ||
| Other undisclosed net income attributable to parent | 10,623 | ||||||
| Net income (loss) attributable to parent: | (57,466) | (67,138) | (31,292) | (10,284) | 5,277 | ||
| Preferred stock dividends and other adjustments | (2,286) | ||||||
| Net income (loss) available to common stockholders, basic: | (57,466) | (67,138) | (31,292) | (10,284) | 2,991 | ||
| Dilutive securities, effect on basic earnings per share | 420 | ||||||
| Other undisclosed net loss available to common stockholders, diluted | (5,213) | ||||||
| Net income (loss) available to common stockholders, diluted: | (57,466) | (67,138) | (31,292) | (10,284) | (1,802) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (68,089) | (67,138) | (31,292) | (10,284) | 5,277 | ||
| Comprehensive income (loss): | (68,089) | (67,138) | (31,292) | (10,284) | 5,277 | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 11,140 | (381) | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (56,949) | (67,519) | (31,292) | (10,284) | 5,277 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.